Merck heads into Q1 earnings with options traders at their most defensive in a year

The Street remains constructive, though with some nuance in recent weeks. Multiple analysts hold Overweight or Outperform ratings, with targets clustered in the $135–$145 range against a current price of $114. Wells Fargo trimmed its target from $150 to $145 on May 1, maintaining Overweight — a signal that the firm still sees meaningful upside but is calibrating expectations after a month-to-date pullback of about 4%. Citigroup reinstated coverage on May 6 with a Neutral rating and a $125 target, sitting materially below the bull camp. The mean target of roughly $130 implies around 14% upside from current levels, consistent with the analyst return potential reading of 13.6%. Valuation has re-rated higher over the past month: the P/E has climbed more than 3 points to 21.5x, while EV/EBITDA is up roughly 1.4 turns to 13.8x — the stock is not cheap on near-term multiples, though the earnings surprise factor score ranks in the 76th percentile, suggesting MRK has a track record of delivering above consensus. EPS estimates are rising on a one-year forward basis, ranking in the 71st percentile, which underpins the bull case. The dividend score, at the 99th percentile, reflects a payout yield of around 3% — meaningful for a large-cap growth-oriented name.

The fundamental debate ahead of next week's call centres on Keytruda's long-term revenue trajectory and what replaces it once loss of exclusivity approaches. The bull case rests on Winrevair's expanding label — recent CADENCE study data for pulmonary hypertension due to heart failure showed strong results — as well as the Cidara acquisition and a cost-saving programme targeting $3B by 2027. The bear case is simpler: Keytruda still dominates the revenue mix, and the pipeline has to execute flawlessly to offset that dependency. Recent earnings have been modestly positive — the April 30 Q4 print moved the stock just over 1% on the day and 1.2% over five days, a subdued reaction. The prior print in February produced a larger 4.4% one-day move. Neither outcome was dramatic, which may partly explain why short interest is light despite the defensive options positioning.

Peer performance this week adds mild context. JNJ gained 2.6% on the week, broadly in line with MRK's 1.7% recovery. AZN and GSK were flatter, up around 1% and 0.6% respectively. The sector has generally recovered ground lost earlier in April, but MRK has not fully closed the gap from its 4% monthly drawdown.

What to watch on May 26: whether Winrevair guidance is raised, how management frames the Keytruda LOE timeline, and whether the options market's elevated put/call ratio reflects caution that proves well-founded or hedges that unwind quickly on a clean print.